Abstract Background and Aims Epicardial adipose tissue (EAT), the visceral fat depot of the
heart, is a modifiable cardio-metbolic risk factor and therapeutic target. Semaglutide and …

Objective Epicardial adipose tissue (EAT), the visceral fat depot of the heart, is a modifiable
cardiovascular risk factor and emerging therapeutic target. Liraglutide, an analog of …

Epicardial adipose tissue is a novel cardiovascular risk factor. It plays a role in the
progression of coronary artery disease, heart failure and atrial fibrillation. Given its rapid …

Background Epicardial adipose tissue (EAT) is a risk factor for cardiovascular diseases.
Glucagon-like peptide 1 analogs (GLP-1A) may have beneficial cardiovascular effects and …

Background Epicardial adipose tissue (EAT) plays an important role in cardiometabolic risk.
EAT is a modifiable risk factor and could be a potential therapeutic target for drugs that …

(1) Sodium–glucose cotransporter-2 inhibitors (SGLT2-i) reduce adipose tissue and
cardiovascular events in patients with type 2 diabetes (T2D). Accumulation of epicardial …

Background Obesity is associated with adverse cardiac remodeling and is a key driver for
the development and progression of heart failure (HF). Once-weekly semaglutide (2.4 mg) …

Aims Human epicardial adipose tissue (EAT) plays a crucial role in the development and
progression of coronary artery disease, atrial fibrillation, and heart failure. Microscopically …

The aim of the study was to assess the effect of sitagliptin addition on the epicardial adipose
tissue (EAT) thickness in subjects with type 2 diabetes mellitus inadequately controlled on …

Obesity is a heterogeneous disease that affects almost one-third of the global population. A
clear association has been established between obesity and cardiovascular disease (CVD) …